Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 35

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 35
---
approval policy and the fees for services performed to that point. All services performed by, and fees paid to, our independent registered public accounting firm during fiscal years 2024 and 2023 were pre-approved in accordance with the pre-approval policies and procedures described above.

Pacira BioSciences, Inc. 2025 Proxy Statement | 43

TABLE OF CONTENTS AUDIT MATTERS

Report of the Audit Committee The Audit Committee is appointed by the board to assist the board in fulfilling its oversight responsibilities with respect to: (1) the integrity of the Company’s consolidated financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory requirements; (2) the qualifications, independence, and performance of the Company’s independent accountants; (3) the performance of the Company’s internal audit function; (4) the Company’s information technology and cybersecurity programs; and (5) other matters as set forth in the charter of the Audit Committee approved by the board. Management is responsible for the Company’s consolidated financial statements and the financial reporting process, including the systems of internal controls and disclosure controls and procedures. The independent accountants are responsible for performing an independent audit of the Company’s consolidated financial statements in accordance with the standards of the PCAOB and issuing a report thereon. The Audit Committee’s responsibility is to monitor and oversee these processes. In connection with these responsibilities, the Audit Committee reviewed and discussed with management and the independent accountants the audited consolidated financial statements of Pacira for the fiscal year ended December 31, 2024. The Audit Committee also discussed with the independent accountants the matters required to be discussed by the applicable requirements of the PCAOB and the SEC. In addition, the Audit Committee received the written disclosures and the letter from the independent accountants required by the applicable requirements of the PCAOB regarding the independent accountants’ communications with the Audit Committee concerning independence and has discussed with the independent accountants the independent accountants’ independence. Based on the reviews and discussions referred to above, the Audit Committee recommended to the board that the audited consolidated financial statements of the Company be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, that was filed with the SEC on February 27, 2025. The Audit Committee of the Board of Directors of Pacira BioSciences, Inc.

| ​ | Alethia YoungChair | ​ | ​ | Abraham Ceesay | ​ | ​ | Mark